PlantForm Corporation is a Canadian biotech company with a low-cost, proprietary manufacturing platform for a wide range of plant-made pharmaceuticals, including monoclonal antibodies, therapeutic proteins and vaccines for the treatment of cancer, HIV/AIDS, Ebola virus and other life-threatening ill…
PlantForm Corporation is a Canadian biotech company with a low-cost, proprietary manufacturing platform for a wide range of plant-made pharmaceuticals, including monoclonal antibodies, therapeutic proteins and vaccines for the treatment of cancer, HIV/AIDS, Ebola virus and other life-threatening illnesses.
The company’s vivoXPRESS® technology uses genetically modified tobacco plants to ‘grow’ biopharmaceuticals in fully contained greenhouse environments. Our plant-based technology delivers high drug expression levels and fully mammalian glycosylation (to eliminate the risk of an unwanted immune system reaction). vivoXPRESS® also provides the following key advantages compared to other fermentation systems for biologic drug production (e.g., mammalian cell culture): - Rapid drug development & production timelines - Versatile manufacturing platform (for new product development) - Unlimited scale-up capability - Low manufacturing costs (approximately one-tenth of mammalian-cell systems)
Team (1)
Sectors PlantForm Corporation serves:
Life Sciences
Health Care
Technology
Join Axial's Private M&A Platform
PlantForm Corporation connects with qualified M&A advisors through the Axial Platform.
Looking for Buyers?
Reach this investor and hundreds more on Axial. No cost to advisors.
